rTMS与药物治疗在晚年难治性抑郁中的疗效比较:两项随机临床试验的个体参与者数据观察性研究
该观察性研究利用两项随机临床试验中758名60岁及以上晚年难治性抑郁(LL-TRD)患者的个体数据,比较rTMS与阿立哌唑增效、安非他酮增效及换用安非他酮的疗效与耐受性。经倾向评分加权和回归调整后,rTMS在治疗开始后10周的MADRS评分及缓解率上均优于三种药物策略,但头痛更常见。结论提示rTMS可能优于药物治疗,支持在LL-TRD治疗流程中更早使用rTMS。
要点
- rTMS组10周MADRS评分较阿立哌唑增效低4.16分(95%CI=2.32,6.00)。
- rTMS组缓解率显著高于三种药物策略(AOR范围3.83–4.87)。
- rTMS组头痛发生率显著高于药物治疗组。
核心结论
- rTMS治疗晚年难治性抑郁可能优于药物治疗,支持在治疗流程中更早使用rTMS。
研究设计与样本
- 观察性研究,使用两项随机对照试验中758名60岁及以上LL-TRD患者的个体参与者数据。
- rTMS试验为每日一次双侧治疗4-6周;药物试验比较阿立哌唑增效、安非他酮增效和换用安非他酮。
- 采用限制、倾向评分加权和回归调整处理试验设计与入组标准差异。
主要发现
- rTMS组10周MADRS评分较阿立哌唑增效低4.16分(95%CI=2.32,6.00)。
- rTMS组10周MADRS评分较安非他酮增效低6.08分(95%CI=4.06,8.09)。
- rTMS组10周MADRS评分较换用安非他酮低6.36分(95%CI=4.55,8.17)。
- rTMS组缓解率(MADRS较基线下降≥50%)较阿立哌唑增效的AOR=3.83(95%CI=1.08,13.56)。
- rTMS组缓解率较安非他酮增效的AOR=4.87(95%CI=1.15,20.68),较换用安非他酮的AOR=4.02(95%CI=1.12,14.47)。
关键数值与推荐
- 主要结局为治疗开始后10周的蒙哥马利-奥斯伯格抑郁评定量表(MADRS)评分。
- 缓解定义为MADRS评分从基线至第10周下降≥50%。
临床怎么用
- 对60岁及以上晚年难治性抑郁患者,可考虑将rTMS作为较药物治疗更早的选项。
- 选择rTMS时需告知患者头痛风险可能高于药物治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors compared the effectiveness and tolerability of repetitive transcranial magnetic stimulation (rTMS) versus pharmacotherapy augmentation and switching strategies in older adults with late-life treatment-resistant depression (LL-TRD). METHODS: This observational study used individual participant data from 758 participants age 60 or older with LL-TRD from two randomized controlled trials: an rTMS trial of once-daily bilateral treatment for 4-6 weeks, and a pharmacotherapy trial comparing aripiprazole augmentation, bupropion augmentation, and switch to bupropion. Restriction, propensity score weighting, and regression adjustment were used to account for differences in trial design and eligibility criteria. The primary outcome was the Montgomery-Åsberg Depression Rating Scale (MADRS) 10 weeks after treatment initiation. RESULTS: After accounting for differences in participant characteristics, rTMS was associated with lower MADRS scores than aripiprazole augmentation (difference: 4.16 points, 95% CI=2.32, 6.00), bupropion augmentation (difference: 6.08 points, 95% CI=4.06, 8.09), and switch to bupropion (difference: 6.36 points, 95% CI=4.55, 8.17). rTMS was also associated with a higher response rate (defined as reduction ≥50% in MADRS score from baseline to week 10) than aripiprazole augmentation (adjusted odds ratio [AOR]=3.83, 95% CI=1.08, 13.56), bupropion augmentation (AOR=4.87, 95% CI=1.15, 20.68), and switch to bupropion (AOR=4.02, 95% CI=1.12, 14.47). Participants who received rTMS were significantly more likely to experience headache than those who received pharmacotherapy. CONCLUSIONS: This analysis suggests that rTMS for LL-TRD may be superior to pharmacotherapy and supports the use of rTMS earlier in the treatment algorithms for LL-TRD.
引用
- Adler E, Blumberger DM, Lenze EJ, et al. Effectiveness of rTMS vs. Pharmacotherapy in Late-Life Treatment-Resistant Depression: An Observational Study of Individual Participant Data From Two Randomized Clinical Trials. Am J Psychiatry. 2026. PMID: 42870348. doi:10.1176/appi.ajp.20260398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。